ASND

Ascendis Pharma A/S ADR

Sep 17 • 03:59PM ET

199.59

+2.35 1.19 %

Healthcare • Biotechnology • Denmark • NASD

Peers: BIIB INCY NBIX REGN VRTX SRPT NKTR DNLI EXEL ADVM

| Held by: IBB CGGR TCAF FDG SPDW AFOS MSSM MEDI ONEQ TMAT

Index	-	P/E	-	EPS (ttm)	-4.97	Insider Own	0.71%	Shs Outstand	60.55M	Perf Week	0.57%
Market Cap	12.09B	Forward P/E	51.13	EPS next Y	3.90	Insider Trans	0.00%	Shs Float	60.12M	Perf Month	2.84%
Enterprise Value	12.44B	PEG	-	EPS next Q	-0.32	Inst Own	104.07%	Short Float	4.46%	Perf Quarter	15.44%
Income	-293.67M	P/S	22.61	EPS this Y	62.52%	Inst Trans	-5.01%	Short Ratio	5.83	Perf Half Y	21.22%
Sales	534.57M	P/B	-	EPS next Y	234.43%	ROA	-28.11%	Short Interest	2.68M	Perf YTD	44.98%
Book/sh	-3.64	P/C	20.84	EPS next 5Y	-	ROE	-	52W High	208.16 -4.12%	Perf Year	67.41%
Cash/sh	9.58	P/FCF	-	EPS past 3/5Y	5.15% -6.13%	ROIC	-175.42%	52W Low	118.03 69.10%	Perf 3Y	92.64%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	249.76% 92.27%	Gross Margin	81.75%	Volatility	2.67% 3.11%	Perf 5Y	39.82%
Dividend TTM	-	EV/Sales	23.26	EPS Y/Y TTM	46.81%	Oper. Margin	-51.56%	ATR (14)	6.27	Perf 10Y	917.80%
Dividend Ex-Date	-	Quick Ratio	0.69	Sales Y/Y TTM	55.77%	Profit Margin	-54.94%	RSI (14)	57.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.02	EPS Q/Q	64.50%	SMA20	1.25%	Beta	0.41	Target Price	249.20
Payout	-	Debt/Eq	-	Sales Q/Q	362.61%	SMA50	7.07%	Rel Volume	0.51	Prev Close	197.24
Employees	-	LT Debt/Eq	-	Earnings	Aug 07 AMC	SMA200	24.90%	Avg Volume	459.53K	Price	199.59
IPO	Jan 28, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.66% 9.03%	Trades		Volume	234,605	Change	1.19%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-03-25	Resumed	Morgan Stanley	Overweight	$250
May-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$250
Apr-16-25	Initiated	RBC Capital Mkts	Outperform	$205
Jan-07-25	Initiated	UBS	Buy	$196
Sep-05-24	Upgrade	Oppenheimer	Perform → Outperform	$180
Jun-25-24	Upgrade	TD Cowen	Hold → Buy	$156 → $175
May-31-24	Initiated	Stifel	Buy	$200
Dec-20-23	Initiated	Jefferies	Buy	$150
Jun-14-23	Resumed	Credit Suisse	Neutral	$89
Apr-05-23	Downgrade	Oppenheimer	Outperform → Perform
Apr-04-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$151 → $108
Apr-03-23	Downgrade	Credit Suisse	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy	$174
Aug-30-22	Resumed	Berenberg	Buy	$166
Mar-28-22	Resumed	Wedbush	Outperform	$163
Mar-15-22	Upgrade	BofA Securities	Neutral → Buy	$148 → $161
Mar-01-22	Initiated	Citigroup	Buy	$187
Feb-14-22	Upgrade	Oppenheimer	Perform → Outperform	$170
Jan-06-22	Initiated	Cowen	Market Perform	$136
Dec-08-21	Initiated	Wells Fargo	Overweight	$176

Show Previous Ratings

Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-14-25 01:16AM	Morgan Stanley Remains Bullish on Ascendis Pharma (ASND) (Insider Monkey)
Sep-02-25 04:01PM	Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 (GlobeNewswire)
Aug-28-25 04:01PM	Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-12-25 10:56AM	Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players (GlobeNewswire)
04:01PM	Loading…
Aug-07-25 04:01PM	Ascendis Pharma Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 04:01PM	Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 (GlobeNewswire)
Jul-28-25 07:00AM	FDA Approves SKYTROFA (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency (GlobeNewswire)
Jul-24-25 11:47PM	Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment (Insider Monkey)
Jul-22-25 10:50AM	Phase II and Phase III Catalyst Monitor: Q3 2025 Outlook Report - Upcoming FDA Decisions Drive Momentum in Biopharma with Key Catalysts Across GHD, PKU, Presbyopia, and Wet AMD Treatments (GlobeNewswire)
Jul-16-25 09:55AM	Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade (Zacks)
Jul-14-25 04:01PM	New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life (GlobeNewswire)
Jul-07-25 04:01PM	Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 (GlobeNewswire)
Jun-24-25 04:25AM	Oppenheimer Hikes Ascendis Pharma Price Target on Strong Yorvipath Demand Outlook (Insider Monkey)
Jun-14-25 08:40AM	Ascendis Pharma price target raised to $224 from $215 at Oppenheimer (TipRanks)
07:43PM	Loading…
Jun-11-25 07:43PM	TransCon hGH Boosts TransCon CNP Results in Kids with Achondroplasia by Week 26 (Insider Monkey)
Jun-10-25 10:39AM	Ascendis reports interim analysis outcomes from achondroplasia trial (Clinical Trials Arena)
Jun-09-25 07:00AM	TransCon hGH Boosted Treatment Benefits of TransCon CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial (GlobeNewswire)
Jun-02-25 08:00AM	FDA Accepts TransCon CNP NDA for Priority Review (GlobeNewswire) +7.89%
May-13-25 10:13PM	Ascendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long Term (Insider Monkey)
04:01PM	New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon CNP (Navepegritide) (GlobeNewswire)
May-12-25 04:45PM	New 4-Year Data Shows Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism (GlobeNewswire)
May-07-25 08:00AM	Rare Stock Picks In April 2025 - From 16 Discerning Analysts (Seeking Alpha)
May-06-25 08:08AM	Launch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1 (Insider Monkey)
May-05-25 08:30AM	Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 (GlobeNewswire)
May-02-25 03:17AM	Ascendis Pharma AS (ASND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ... (GuruFocus.com)
May-01-25 09:35PM	Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:01PM	Ascendis Pharma Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 02:29PM	Growth Is Priced Out Of Novo Nordisk (Seeking Alpha)
Apr-24-25 04:01PM	Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 (GlobeNewswire)
01:15AM	Loading…
01:15AM	Artisan Mid Cap Fund Q1 2025 Commentary (Seeking Alpha)
Apr-17-25 11:00AM	Reddit initiated, Target downgraded: Wall Streets top analyst calls (TipRanks)
Apr-16-25 09:40AM	Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? (Zacks)
Apr-14-25 04:38PM	Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (Seeking Alpha)
02:03PM	Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires? (Insider Monkey)
Mar-31-25 04:01PM	Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia (GlobeNewswire)
Mar-18-25 09:49AM	Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock? (Zacks)
Feb-24-25 04:01PM	Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-14-25 12:00AM	Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ... (GuruFocus.com)
Feb-13-25 02:40PM	Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? (Benzinga) +12.96%
Feb-12-25 04:05PM	Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs (GlobeNewswire) +5.55%
04:01PM	Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-05-25 04:01PM	Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 (GlobeNewswire) +5.86%
Feb-04-25 07:23AM	Alibaba Cloud integrates DeepSeeks AI models (Verdict)
Jan-23-25 02:17AM	Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now? (Insider Monkey)
Jan-12-25 05:00PM	Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-25 08:30AM	Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 08:30AM	YORVIPATH (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults (GlobeNewswire)
Dec-18-24 06:28AM	Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk (TipRanks)
Dec-16-24 08:30AM	New InsiGHTS Trial of TransCon hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26 (GlobeNewswire) +5.18%
Dec-12-24 04:01PM	FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency (GlobeNewswire)
Dec-11-24 11:09AM	Er-Kim and Ascendis endocrine therapy agreement extended in Eurasia (Pharmaceutical Technology)
Dec-10-24 07:00AM	Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets (GlobeNewswire)
Nov-14-24 04:01PM	Ascendis Pharma Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-07-24 04:01PM	Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 (GlobeNewswire)
Nov-05-24 12:12PM	Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA (Pharmaceutical Technology)
10:00AM	Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology (GuruFocus.com)
07:27AM	Ascendis Pharma and Novo Nordisk Join Forces (TipRanks)
07:10AM	Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform (TipRanks)
Nov-04-24 03:30PM	Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug (Quartz)
01:34PM	Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug (Benzinga)
07:00AM	Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases (GlobeNewswire)
Oct-01-24 10:13AM	Ascendis Pharma submits sBLA for growth hormone deficiency therapy (Pharmaceutical Technology)
Sep-30-24 08:30AM	New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide) Presented at ASBMR 2024 (GlobeNewswire)
08:30AM	Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency (GlobeNewswire)
Sep-25-24 03:50PM	BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish (Benzinga)
Sep-19-24 08:16PM	Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs (GlobeNewswire)
Sep-18-24 04:04PM	Ascendis Pharma A/S Announces Proposed Public Offering of ADSs (GlobeNewswire)
Sep-17-24 09:02AM	Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last? (Zacks) +5.03%
01:30AM	RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares (GuruFocus.com)
Sep-16-24 04:01PM	Ascendis Rockets And Hammers BioMarin On New Results For Growth Drug (Investor's Business Daily) +17.07%
03:12PM	Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term (Benzinga)
07:00AM	Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo (GlobeNewswire)
Sep-14-24 07:54PM	Ascendis Pharma A/S (ASND): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-13-24 08:30AM	Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024 (GlobeNewswire)
Sep-11-24 05:37PM	Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults (GlobeNewswire)
Sep-04-24 05:02PM	Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In (Benzinga) -11.27%
04:48PM	Why Ascendis Pharma Stock Tumbled by 11% Today (Motley Fool)
04:02PM	Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance Cut (Investor's Business Daily)
09:14AM	Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout (Investor's Business Daily)
Sep-03-24 05:14PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
05:06PM	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (GlobeNewswire)
05:04PM	Ascendis Pharma Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Sep-02-24 09:01AM	Ascendis Pharma A/S (ASND) Q2 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-28-24 08:30AM	Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024 (GlobeNewswire)
Aug-14-24 12:31PM	Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath (Zacks)
08:59AM	Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains? (Zacks)
Aug-13-24 04:32AM	FDA approves Ascendis Pharmas YORVIPATH for hypoparathyroidism (Pharmaceutical Technology) +8.70%
Aug-12-24 04:55PM	Ascendis Pharma Zips Higher After FDA Approves Embattled Drug (Investor's Business Daily)
07:30AM	FDA approves Ascendis drug for rare endocrine condition (BioPharma Dive)
07:00AM	FDA Approves YORVIPATH (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults (GlobeNewswire)
Jul-07-24 09:01AM	2 Biotech Stocks With Big FDA Decisions Approaching Heres What Analysts Expect (TipRanks)
Jul-05-24 06:33AM	Pendopharm and Ascendis to distribute hypoparathyroidism treatment (Pharmaceutical Technology)
Jul-04-24 12:48PM	Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon PTH in Canada (PR Newswire)
Jun-24-24 04:45PM	Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024 (GlobeNewswire)
Jun-21-24 01:02AM	Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand (Insider Monkey) +5.12%
Jun-04-24 04:01PM	Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-24 04:01PM	Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 (GlobeNewswire)
May-30-24 08:30AM	Ascendis to Spotlight Latest Updates for TransCon Rare Endocrinology Disease Portfolio at ENDO 2024 (GlobeNewswire)
May-15-24 01:57PM	FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months (Benzinga)

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
JENSEN FLEMMING STEEN	Officer	Sep 09 '25	Proposed Sale	203.70	5,000	1,018,503	Sep 09 04:12 PM
JENSEN MICHAEL WOLFF	Officer	Aug 29 '25	Proposed Sale	193.00	5,000	965,000	Aug 29 04:00 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Aug 27 '25	Proposed Sale	193.94	3,036	588,814	Aug 27 04:06 PM
Jan Moller Mikkelsen	President and Chief Executive	Aug 20 '25	Proposed Sale	192.79	3,000	578,385	Aug 20 05:34 PM
JENSEN MICHAEL WOLFF	Officer	Aug 15 '25	Proposed Sale	194.82	9,375	1,826,403	Aug 15 04:15 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Aug 14 '25	Proposed Sale	191.60	25,000	4,789,998	Aug 14 04:13 PM
JENSEN FLEMMING STEEN	Officer	Aug 13 '25	Proposed Sale	191.32	10,000	1,913,225	Aug 13 05:18 PM
Morrison Lisa	Director	Aug 13 '25	Proposed Sale	191.07	2,158	412,319	Aug 13 04:22 PM
SMITH SCOTT THOMAS	Officer	Aug 12 '25	Proposed Sale	192.57	10,000	1,925,734	Aug 12 05:01 PM
Shu Aimee	Officer	May 12 '25	Proposed Sale	154.80	2,018	312,384	May 12 12:13 PM
JENSEN FLEMMING STEEN	Officer	May 07 '25	Proposed Sale	162.20	10,938	1,774,164	May 07 05:02 PM
Shu Aimee	Officer	May 06 '25	Proposed Sale	166.61	4,204	700,412	May 07 07:18 AM
SPROGOE KENNETT	Officer	May 06 '25	Proposed Sale	170.05	10,000	1,700,485	May 06 04:11 PM
JENSEN MICHAEL WOLFF	Officer	May 05 '25	Proposed Sale	170.99	4,386	749,948	May 05 04:14 PM
JENSEN MICHAEL WOLFF	Officer	Mar 07 '25	Proposed Sale	146.46	4,000	585,846	Mar 07 05:03 PM
JENSEN FLEMMING STEEN	Officer	Mar 06 '25	Proposed Sale	152.39	10,000	1,523,933	Mar 06 04:35 PM
JENSEN MICHAEL WOLFF	Officer	Mar 06 '25	Proposed Sale	152.25	1,614	245,735	Mar 06 04:35 PM
MIKKELSEN JAN MOLLER	Officer	Mar 05 '25	Proposed Sale	155.13	7,789	1,208,292	Mar 05 04:51 PM
Bodenhoff Mads	Officer	Mar 05 '25	Proposed Sale	155.01	2,254	349,403	Mar 05 02:31 PM
Hartvig Camilla Harder	Officer	Mar 04 '25	Proposed Sale	152.12	2,222	338,021	Mar 04 08:38 PM
Bodenhoff Mads	Officer	Mar 04 '25	Proposed Sale	152.12	2,828	430,208	Mar 04 08:32 PM
Fairey William	Director	Mar 04 '25	Proposed Sale	152.12	1,006	153,037	Mar 04 08:27 PM
IMANI SIHAM	Director	Mar 04 '25	Proposed Sale	152.12	1,006	153,037	Mar 04 08:22 PM
Morrison Lisa	Director	Mar 04 '25	Proposed Sale	152.12	1,470	223,623	Mar 04 08:15 PM
HOLTUG LARS	Director	Mar 04 '25	Proposed Sale	152.12	1,470	223,623	Mar 04 08:12 PM
Cha Albert	Director	Mar 04 '25	Proposed Sale	152.12	1,470	223,623	Mar 04 08:09 PM
SINGEL STINA	Officer	Mar 04 '25	Proposed Sale	152.12	13,344	2,029,949	Mar 04 08:04 PM
SMITH SCOTT THOMAS	Officer	Mar 04 '25	Proposed Sale	152.12	13,344	2,029,949	Mar 04 08:00 PM
JENSEN MICHAEL WOLFF	Officer	Mar 04 '25	Proposed Sale	152.12	13,344	2,029,949	Mar 04 07:55 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Mar 04 '25	Proposed Sale	152.12	7,719	1,174,249	Mar 04 07:50 PM
SPROGOE KENNETT	Officer	Mar 04 '25	Proposed Sale	152.12	7,719	1,174,249	Mar 04 07:45 PM
JENSEN FLEMMING STEEN	Officer	Mar 04 '25	Proposed Sale	152.12	7,719	1,174,249	Mar 04 07:40 PM
MIKKELSEN JAN MOLLER	Officer	Mar 03 '25	Proposed Sale	155.14	7,800	1,210,089	Mar 03 04:58 PM
SINGEL STINA	Officer	Feb 20 '25	Proposed Sale	155.20	2,729	423,542	Feb 21 06:11 AM
SMITH SCOTT THOMAS	Officer	Feb 20 '25	Proposed Sale	154.27	10,000	1,542,671	Feb 20 04:15 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Feb 19 '25	Proposed Sale	152.70	39,375	6,012,750	Feb 19 05:06 PM
JENSEN MICHAEL WOLFF	Officer	Feb 19 '25	Proposed Sale	151.32	5,000	756,607	Feb 19 04:56 PM
JENSEN FLEMMING STEEN	Officer	Feb 18 '25	Proposed Sale	146.80	10,000	1,467,977	Feb 18 05:30 PM
SINGEL STINA	Officer	Dec 10 '24	Proposed Sale	129.13	2,119	273,621	Dec 10 05:16 PM
JENSEN MICHAEL WOLFF	Officer	Dec 10 '24	Proposed Sale	129.13	2,119	273,621	Dec 10 05:07 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Dec 10 '24	Proposed Sale	129.13	1,222	157,794	Dec 10 05:02 PM
SPROGOE KENNETT	Officer	Dec 10 '24	Proposed Sale	129.13	1,222	157,794	Dec 10 04:59 PM
SMITH SCOTT THOMAS	Officer	Dec 10 '24	Proposed Sale	129.13	2,119	273,621	Dec 10 04:58 PM
JENSEN FLEMMING STEEN	Officer	Dec 10 '24	Proposed Sale	129.13	1,222	157,794	Dec 10 04:55 PM
MIKKELSEN JAN MOLLER	Officer	Dec 10 '24	Proposed Sale	129.13	5,292	683,342	Dec 10 04:44 PM
JENSEN FLEMMING STEEN	Officer	Dec 03 '24	Proposed Sale	131.37	9,375	1,231,574	Dec 03 04:35 PM
Hartvig Camilla Harder	Officer	Nov 19 '24	Proposed Sale	122.38	19,468	2,382,402	Nov 19 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ASND

Ascendis Pharma A/S ADR

Upgrade your FINVIZ experience